HomeCompareIDRSF vs ADC

IDRSF vs ADC: Dividend Comparison 2026

IDRSF yields 48.90% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDRSF wins by $195.3K in total portfolio value
10 years
IDRSF
IDRSF
● Live price
48.90%
Share price
$4.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$372.2K
Annual income
$74,100.38
Full IDRSF calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — IDRSF vs ADC

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDRSFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDRSF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDRSF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF
Annual income on $10K today (after 15% tax)
$4,156.48/yr
After 10yr DRIP, annual income (after tax)
$62,985.32/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $4,714.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + ADC for your $10,000?

IDRSF: 50%ADC: 50%
100% ADC50/50100% IDRSF
Portfolio after 10yr
$274.6K
Annual income
$76,873.81/yr
Blended yield
28.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

IDRSF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-10.1
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys
0
ADC buys
0
No recent congressional trades found for IDRSF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDRSFADC
Forward yield48.90%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$372.2K$176.9K
Annual income after 10y$74,100.38$79,647.25
Total dividends collected$295.4K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: IDRSF vs ADC ($10,000, DRIP)

YearIDRSF PortfolioIDRSF Income/yrADC PortfolioADC Income/yrGap
1← crossover$15,590$4,889.98$10,987$577.21+$4.6KIDRSF
2$23,806$7,124.73$12,293$855.34+$11.5KIDRSF
3$35,640$10,167.77$14,088$1,290.70+$21.6KIDRSF
4$52,361$14,226.41$16,660$1,994.91+$35.7KIDRSF
5$75,560$19,533.63$20,525$3,181.85+$55.0KIDRSF
6$107,194$26,344.00$26,654$5,286.90+$80.5KIDRSF
7$149,625$34,927.92$37,006$9,259.47+$112.6KIDRSF
8$205,663$45,564.28$55,862$17,338.74+$149.8KIDRSF
9$278,591$58,531.92$93,452$35,300.32+$185.1KIDRSF
10$372,193$74,100.38$176,931$79,647.25+$195.3KIDRSF

IDRSF vs ADC: Complete Analysis 2026

IDRSFStock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this IDRSF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHDIDRSF vs JEPIIDRSF vs OIDRSF vs KOIDRSF vs MAINIDRSF vs NNNIDRSF vs EPRTIDRSF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.